Literature DB >> 1881367

High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii.

R Zangerle1, F Allerberger, P Pohl, P Fritsch, M P Dierich.   

Abstract

We studied 41 AIDS patients in the Austrian Tyrol with respect to toxoplasma antibody titers and the presence of CNS toxoplasmosis. In no patient had primary Pneumocystis carinii pneumonia (PcP) prophylaxis with either trimethoprim/sulfamethoxazole or pyrimethamine/sulfadoxine been applied; the degree to which CNS toxoplasmosis is influenced by this kind of PcP chemoprophylaxis, widely used elsewhere, is still unclear. In this study 47.4% of toxoplasma-seropositive patients developed CNS toxoplasmosis, compared to the previously estimated risk of 12%-28% for developing CNS involvement in such patients. In view of the high risk of toxoplasma-seropositive patients with AIDS, increased efforts in developing a well-tolerated chemoprophylaxis to combat CNS toxoplasmosis are required.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1881367     DOI: 10.1007/bf00193846

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  19 in total

Review 1.  Prophylaxis of Pneumocystis carinii pneumonia: an update.

Authors:  J A Kovacs; H Masur
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226

2.  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases.

Authors: 
Journal:  MMWR Suppl       Date:  1987-08-14

3.  Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome.

Authors:  J A Cohn; A McMeeking; W Cohen; J Jacobs; R S Holzman
Journal:  Am J Med       Date:  1989-05       Impact factor: 4.965

Review 4.  AIDS commentary. Toxoplasmic encephalitis.

Authors:  B J Luft; J S Remington
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

5.  Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS.

Authors:  I H Grant; J W Gold; M Rosenblum; D Niedzwiecki; D Armstrong
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

6.  A retrospective study about the use of cotrimoxazole as diagnostic support and treatment of suspected cerebral toxoplasmosis in AIDS.

Authors:  P Solbreux; J Sonnet; F Zech
Journal:  Acta Clin Belg       Date:  1990       Impact factor: 1.264

7.  Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patients.

Authors:  P M Girard; R Landman; C Gaudebout; A Lepretre; P Lottin; C Michon; P De Truchis; S Matheron; F Camus; R Farinotti
Journal:  Lancet       Date:  1989-06-17       Impact factor: 79.321

8.  Serological study of the prevalence of toxoplasmosis in 167 patients with acquired immunodeficiency syndrome (AIDS) or chronic lymphadenopathy syndrome (LAS).

Authors:  F Derouin; B Beauvais; M Larivière
Journal:  Biomed Pharmacother       Date:  1986       Impact factor: 6.529

Review 9.  Pneumocystis carinii and Toxoplasma gondii infections in patients with AIDS.

Authors:  J Mills
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

10.  Assessment of therapy for toxoplasma encephalitis. The TE Study Group.

Authors:  H W Haverkos
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

View more
  18 in total

1.  Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virus.

Authors:  C Leport; J Franck; G Chene; F Derouin; J L Ecobichon; S Pueyo; J M Miro; B J Luft; P Morlat; H Dumon
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade.

Authors:  Rajarshi Bhadra; Jason P Gigley; Louis M Weiss; Imtiaz A Khan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

3.  Pyrimethamine alone as prophylaxis for cerebral toxoplasmosis in patients with advanced HIV infection.

Authors:  H Klinker; P Langmann; E Richter
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

4.  Seroprevalence of toxoplasmosis in diabetic pregnant women in southwestern of Iran.

Authors:  Jasem Saki; Shahla Shafieenia; Masoud Foroutan-Rad
Journal:  J Parasit Dis       Date:  2016-01-23

5.  Detection of toxoplasmosis in patients with end-stage renal disease by enzyme-linked immunosorbent assay and polymerase chain reaction methods.

Authors:  J Saki; S Khademvatan; S Soltani; H Shahbazian
Journal:  Parasitol Res       Date:  2012-09-20       Impact factor: 2.289

6.  Diagnosis and Treatment of Toxoplasmosis of the CNS in Patients with AIDS.

Authors:  C Katlama
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

7.  Real-time PCR for quantitative detection of Toxoplasma gondii.

Authors:  M H Lin; T C Chen; T T Kuo; C C Tseng; C P Tseng
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

8.  Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS.

Authors:  H Klinker; P Langmann; E Richter
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

9.  Risk factors for severe disease due to Toxoplasma gondii in HIV-positive patients.

Authors:  H J Stellbrink; R Führer-Burow; A Raedler; H Albrecht; S Fenske
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

10.  Toxoplasma gondii seroprevalence in Mali.

Authors:  Dinkorma T Ouologuem; Abdoulaye A Djimdé; Nouhoum Diallo; Ogobara K Doumbo; David S Roos
Journal:  J Parasitol       Date:  2012-08-27       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.